ESTRING
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ESTRING (ESTRING).
Estradiol is a steroid hormone that binds to and activates estrogen receptors (ERα and ERβ), leading to modulation of gene expression and subsequent physiological effects including proliferation and differentiation of reproductive tissues, maintenance of bone density, and regulation of lipid metabolism.
| Metabolism | Estradiol is metabolized primarily in the liver via oxidation (cytochrome P450 1A2, 3A4, 1A1, 1B1) and conjugation (glucuronidation and sulfation). |
| Excretion | Renal: approximately 90% as glucuronide and sulfate conjugates; fecal: approximately 10% as conjugates; enterohepatic recirculation occurs. |
| Half-life | Terminal elimination half-life is approximately 13-20 hours; clinical context: provides sustained estradiol levels for local estrogenic effects with minimal systemic accumulation. |
| Protein binding | Estradiol is approximately 98% bound to plasma proteins, primarily to sex hormone-binding globulin (SHBG) and albumin. |
| Volume of Distribution | Vd is approximately 1.2 L/kg; indicates extensive distribution into tissues, including estrogen-responsive organs. |
| Bioavailability | Vaginal: local bioavailability is high, with systemic absorption producing estradiol levels similar to early follicular phase; systemic bioavailability relative to oral estradiol is lower due to first-pass effect avoidance but variable (approximately 10-20% of an oral dose). |
| Onset of Action | Vaginal: local effects on urogenital epithelium observed within 2-4 weeks of continuous use. |
| Duration of Action | Vaginal: sustained local effects for up to 90 days per ring; ring is replaced every 3 months to maintain efficacy. |
| Molecular Weight | 272.38 |
One vaginal ring (2 mg estradiol) inserted into the upper third of the vagina every 90 days.
| Dosage form | INSERT, EXTENDED RELEASE |
| Renal impairment | No specific dosage adjustment required; manufacturer does not provide GFR-based guidelines. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C); use with caution in mild to moderate impairment (Child-Pugh A or B) and consider dose reduction. |
| Pediatric use | Not indicated for use in pediatric patients. |
| Geriatric use | Use lowest effective dose; monitor for endometrial cancer, cardiovascular events, and dementia risk; same dosing schedule as adults. |
| 1st trimester | Estradiol is contraindicated in pregnancy. Use in first trimester may cause fetal harm; estrogens should not be used during pregnancy. |
| 2nd trimester | Contraindicated. Estradiol may adversely affect fetal development; avoid use. |
| 3rd trimester | Contraindicated. Use during third trimester may be associated with urogenital anomalies and other adverse effects. |
Clinical note
Comprehensive clinical and safety monograph for ESTRING (ESTRING).
| Placental transfer | Estradiol crosses the placenta and can be detected in fetal tissues. |
| Breastfeeding | Estradiol is excreted in human breast milk and may reduce milk production. Use with caution, especially in nursing mothers of preterm infants; consider alternatives. |
| Lactation Rating |
■ FDA Black Box Warning
Estrogen-alone therapy: Increased risk of endometrial cancer in women with a uterus. Use progestin if uterus is intact. Not for prevention of cardiovascular disease or dementia.
| Serious Effects |
Known or suspected pregnancyUndiagnosed abnormal genital bleedingKnown or suspected breast cancerKnown or suspected estrogen-dependent neoplasiaActive or past history of venous thromboembolismKnown thrombophilic disordersActive or recent arterial thromboembolic diseaseHypersensitivity to estradiol or any componentHepatic impairment or disease
| Precautions | Endometrial cancer, Cardiovascular disorders, Dementia, Gallbladder disease, Hypercalcemia, Retinal vascular thrombosis, Fluid retention, Hypothyroidism, Angioedema, Exacerbation of asthma, diabetes, epilepsy, migraine, porphyria, SLE, hepatic hemangiomas |
| Food/Dietary | No significant food interactions. Grapefruit juice does not affect estradiol administered vaginally. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | Estradiol is contraindicated in pregnancy. Use during first trimester is associated with congenital anomalies including cardiovascular and limb defects. Second and third trimester exposure may cause urogenital abnormalities and subsequent reproductive tract anomalies in offspring. Estrogens should not be used during pregnancy. |
| Fetal Monitoring | Monitor maternal blood pressure, signs of thromboembolism, and uterine bleeding. Fetal monitoring not applicable as use is contraindicated in pregnancy. |
| Fertility Effects | Estradiol does not impair fertility when used as indicated; however, it may interfere with conception by suppressing ovulation at high doses. Use as vaginal ring for local estrogen therapy unlikely to affect fertility. |
| Clinical Pearls | ESTRING (estradiol vaginal ring) delivers local estrogen therapy for urogenital atrophy. It is not indicated for systemic menopausal symptoms. The ring is replaced every 90 days. For optimal effectiveness, ensure the ring is placed high in the vaginal vault. If discomfort occurs, the ring may be too low. Do not use in patients with known or suspected pregnancy, undiagnosed abnormal genital bleeding, or history of breast cancer. Caution in patients with endometriosis or thromboembolic disorders. |
| Patient Advice | Insert the ring high into the vagina, similar to a tampon, and leave it in place for 90 days. · The ring can be removed for up to 2 hours during intercourse if desired, but rinse with lukewarm water before reinsertion. · Do not use oil-based lubricants or douches as they may damage the ring. · Contact your healthcare provider if the ring falls out or if you experience vaginal bleeding, pain, or signs of infection. · The ring does not protect against sexually transmitted infections or pregnancy. · Dispose of used rings in the trash, not down the toilet. |